Eli Lilly to invest more than $1 billion in India manufacturing partnerships

Eli Lilly said on October 6 that it plans to invest more than $1 billion in India over the coming years to expand manufacturing and medicine supply through partnerships with local drugmakers ^[1].

The company said the collaborations are meant to increase the availability of its key drugs, including medicines for obesity, diabetes, Alzheimer's disease, cancer and autoimmune conditions ^[1]. Lilly does not currently operate its own manufacturing facility in India, a country that is home to many companies that make complex drugs, vials and injectables on a contract basis for larger pharmaceutical firms ^[1].

Lilly is "actively engaging with contract manufacturers in India," the company told Reuters, but it did not disclose which manufacturers it is working with or which medicines they would make ^[1].

"We are making significant investments to increase manufacturing and medicine supply capacity around the world," said Patrik Jonsson, president of Lilly International, who described India as a hub for capability building within the company's global network ^[1].

The India plans come as drugmakers rush to add U.S. manufacturing capacity after the Trump administration imposed a 100% tariff on imported branded and patented drugs beginning October 1 ^[1]. In September, Lilly announced a $5 billion investment in a new facility in Virginia, part of a $27 billion expansion plan to build four new U.S. plants over the next five years ^[1].

Lilly launched Mounjaro, its tirzepatide drug, in India this year ^[1]. Novo Nordisk's Wegovy, whose main ingredient is semaglutide, also launched there, and sales of both drugs doubled within months of their introductions ^[1]. The launches have raised patient awareness of obesity treatments in a country projected to have the world's second-largest obese population by 2050 ^[1].

Lilly is also setting up a manufacturing and quality facility in the southern Indian city of Hyderabad. The hub will oversee the company's contract manufacturing network across India and provide technical capabilities, Lilly said ^[1]. Recruitment "will begin immediately," the company said, with plans to hire engineers, chemists, analytical scientists, quality control and assurance experts, and managers ^[1].

Lilly is also preparing for competition from Indian generic drugmakers that are racing to launch cheaper versions of Wegovy once semaglutide goes off patent next year ^[1].

Why it matters for patients

Lilly's India spending is part of a broader effort by the company to add manufacturing capacity, and the company says the goal is to increase supply of its key drugs, a category that includes its obesity and diabetes treatments ^[1].

What the announcement does not say is how, or whether, it will change supply, availability or prices in the United States. Lilly did not disclose which contract manufacturers it is working with, which products they will make, where those products will be sold, or how the money will be divided among partners ^[1]. It also gave no timeline beyond "the coming years" ^[1].

The generic competition Lilly is bracing for is specific to semaglutide, the ingredient in Novo Nordisk's Wegovy, which the report says goes off patent next year ^[1]. Tirzepatide, the ingredient in Lilly's Mounjaro, is a different molecule and is not described that way ^[1].

What happens next

Lilly said recruitment for the Hyderabad manufacturing and quality site "will begin immediately," with hiring for engineers, chemists, analytical scientists, quality control and assurance experts, and managers ^[1]. The company gave no date for when Indian contract manufacturing capacity would come online ^[1].

On the U.S. side, Lilly's $27 billion plan calls for four new plants over five years, and the $5 billion Virginia facility was announced in September ^[1]. The 100% tariff on imported branded and patented drugs took effect October 1 ^[1]. Cheaper Indian versions of semaglutide are expected after the patent expires next year, but no specific date was given ^[1].